Literature DB >> 27167974

Common and Rare Manifestations of Neuromyelitis Optica Spectrum Disorder.

Dominique Rosales1, Ilya Kister2.   

Abstract

The discovery of a highly specific biomarker of neuromyelitis optica (NMO)-the anti-aquaporin-4 (AQP4) antibody-has opened new paths to understanding disease pathogenesis and afforded a way to confirm the diagnosis in clinical practice. An important consequence of the discovery is the broadening of the spectrum of syndromes seen in the context of AQP4 autoimmunity. These syndromes have been subsumed under the rubric of NMO spectrum disorder (NMOSD). The current classification recognizes not only optic neuritis and myelitis as core syndromes of NMOSD but also cerebral, diencephalic, brainstem, and area postrema syndromes. These neurologic syndromes are the focus of our review. AQP4 is also expressed in many organs outside of the central nervous system, and this may explain some of the unusual, non-neurologic features that have been occasionally reported in NMOSD. Our review catalogues non-neurologic manifestations seen in NMOSD and concludes with a discussion of frequently associated autoimmune and neoplastic comorbidities of NMOSD.

Entities:  

Keywords:  Aquaporin-4; Comorbidities; Neuromyelitis optica; Optic neuritis; Transverse myelitis

Mesh:

Substances:

Year:  2016        PMID: 27167974     DOI: 10.1007/s11882-016-0619-4

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  88 in total

1.  Neuromyelitis optica (Devic's syndrome) as first manifestation of systemic lupus erythematosus.

Authors:  C Jacobi; K Stingele; R Kretz; M Hartmann; B Storch-Hagenlocher; A Breitbart; B Wildemann
Journal:  Lupus       Date:  2006       Impact factor: 2.911

Review 2.  Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature.

Authors:  Sven Jarius; Brigitte Wildemann
Journal:  Brain Pathol       Date:  2013-11       Impact factor: 6.508

3.  Paraneoplastic neuromyelitis optica spectrum disorder associated with stomach carcinoid tumor.

Authors:  Talal Al-Harbi; Adnan Al-Sarawi; Mohamed Binfalah; Said Dermime
Journal:  Hematol Oncol Stem Cell Ther       Date:  2014-06-20

4.  Neuromyelitis optica in patients with myasthenia gravis who underwent thymectomy.

Authors:  Ilya Kister; Sandeep Gulati; Cavit Boz; Roberto Bergamaschi; Giovanni Piccolo; Guiseppe Piccolo; Joel Oger; Michael L Swerdlow
Journal:  Arch Neurol       Date:  2006-06

5.  Neuromyelitis optica in a patient with pemphigus foliaceus.

Authors:  R Salazar; M Cerghet; E Farhat; H W Lim
Journal:  J Neurol Sci       Date:  2012-05-24       Impact factor: 3.181

6.  Wall-eyed bilateral internuclear ophthalmoplegia (WEBINO) syndrome in a patient with neuromyelitis optica spectrum disorder and anti-aquaporin-4 antibody.

Authors:  Koji Shinoda; Takuya Matsushita; Konosuke Furuta; Noriko Isobe; Tomomi Yonekawa; Yasumasa Ohyagi; Jun-ichi Kira
Journal:  Mult Scler       Date:  2011-02-07       Impact factor: 6.312

7.  Brain abnormalities in neuromyelitis optica.

Authors:  Sean J Pittock; Vanda A Lennon; Karl Krecke; Dean M Wingerchuk; Claudia F Lucchinetti; Brian G Weinshenker
Journal:  Arch Neurol       Date:  2006-03

8.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.

Authors:  Dean M Wingerchuk; Brenda Banwell; Jeffrey L Bennett; Philippe Cabre; William Carroll; Tanuja Chitnis; Jérôme de Seze; Kazuo Fujihara; Benjamin Greenberg; Anu Jacob; Sven Jarius; Marco Lana-Peixoto; Michael Levy; Jack H Simon; Silvia Tenembaum; Anthony L Traboulsee; Patrick Waters; Kay E Wellik; Brian G Weinshenker
Journal:  Neurology       Date:  2015-06-19       Impact factor: 9.910

9.  Neuromyelitis optica spectrum disorders without and with autoimmune diseases.

Authors:  Bingjun Zhang; Yi Zhong; Yanqiang Wang; Yongqiang Dai; Wei Qiu; Lei Zhang; Haiyan Li; Zhengqi Lu
Journal:  BMC Neurol       Date:  2014-08-19       Impact factor: 2.474

10.  Paraneoplastic neuromyelitis optica associated with ANNA-1 antibodies in invasive thymoma.

Authors:  Hee Kyung Yang; Se Joon Woo; Woong-Yang Park; Jeong-Min Hwang
Journal:  BMC Ophthalmol       Date:  2014-09-03       Impact factor: 2.209

View more
  7 in total

1.  Association of severe and therapy-refractory systemic lupus erythematosus and neuromyelitis optica: a management challenge.

Authors:  Inês Furtado; Guiomar Pinheiro; Ana Campar; Teresa Mendonça
Journal:  BMJ Case Rep       Date:  2018-06-04

2.  Anti-IL-6 Therapies for Neuromyelitis Optica Spectrum Disorders: A Systematic Review of Safety and Efficacy.

Authors:  Itay Lotan; Richard McGowan; Michael Levy
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

3.  Importance of Regular and Maintenance Therapy Adherence in Neuromyelitis Optica (NMO): Lessons from a Repeating Relapse Case.

Authors:  Jing Miao; Doreen E Aboagye; Boris Chulpayev; Lin Liu; Gary Ishkanian; Bangaruraju Kolanuvada; Dariush Alaie; Richard L Petrillo
Journal:  Am J Case Rep       Date:  2018-01-11

4.  NMOSD-Diagnostic Dilemmas Leading towards Final Diagnosis.

Authors:  Anna K Szewczyk; Ewa Papuć; Krystyna Mitosek-Szewczyk; Michał Woś; Konrad Rejdak
Journal:  Brain Sci       Date:  2022-07-06

Review 5.  Neuroimmunological Implications of AQP4 in Astrocytes.

Authors:  Hiroko Ikeshima-Kataoka
Journal:  Int J Mol Sci       Date:  2016-08-10       Impact factor: 5.923

Review 6.  Complexity and wide range of neuromyelitis optica spectrum disorders: more than typical manifestations.

Authors:  Jinming Han; Meng-Ge Yang; Jie Zhu; Tao Jin
Journal:  Neuropsychiatr Dis Treat       Date:  2017-10-20       Impact factor: 2.570

Review 7.  Cognitive impairment in NMOSD-More questions than answers.

Authors:  Dominika Czarnecka; Magdalena Oset; Iwona Karlińska; Mariusz Stasiołek
Journal:  Brain Behav       Date:  2020-10-06       Impact factor: 2.708

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.